Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
67 hedge funds and large institutions have $58M invested in Cascadian Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 6 closing their positions.
208% more call options, than puts
Call options by funds: $2.36M | Put options by funds: $767K
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
6% more funds holding
Funds holding: 63 → 67 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $62.8M → $58M (-$4.81M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$3.43M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$3.33M |
| 3 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$989K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$862K |
| 5 |
First Eagle Investment Management
New York
|
+$652K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$2.62M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.29M |
| 3 |
PC
PointState Capital
New York
|
-$1.03M |
| 4 |
Renaissance Technologies
New York
|
-$1.03M |
| 5 |
Goldman Sachs
New York
|
-$436K |
CASC Hedge Fund Activity: Q4 2013 in Review
67 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2013, worth a combined $58M — down 7.7% from $62.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CASC positions and 6 closed out — a net gain of 4 holders — while 22 added to existing stakes and 13 trimmed.
The largest buyer was QVT Financial, adding an estimated $3.43M. The largest seller was First Manhattan, cutting an estimated $2.62M.
- 67 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2013, up from 63 in Q3 2013.
- Funds reported $58M of Cascadian Therapeutics, Inc. stock for Q4 2013, down 7.7% quarter-over-quarter.
- 10 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2013 and 6 closed out, a net change of +4 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q4 2013 was QVT Financial, an estimated $3.43M added.
- The largest Cascadian Therapeutics, Inc. seller in Q4 2013 was First Manhattan, an estimated $2.62M sold.
Based on aggregated 13F filings for Q4 2013.